PMID- 26863991
OWN - NLM
STAT- MEDLINE
DCOM- 20170106
LR  - 20220129
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 18
IP  - 5
DP  - 2016 May
TI  - L-arginine promotes gut hormone release and reduces food intake in rodents.
PG  - 508-18
LID - 10.1111/dom.12644 [doi]
AB  - AIMS: To investigate the anorectic effect of L-arginine (L-Arg) in rodents. 
      METHODS: We investigated the effects of L-Arg on food intake, and the role of the 
      anorectic gut hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), the 
      G-protein-coupled receptor family C group 6 member A (GPRC6A) and the vagus nerve 
      in mediating these effects in rodents. RESULTS: Oral gavage of L-Arg reduced food 
      intake in rodents, and chronically reduced cumulative food intake in diet-induced 
      obese mice. Lack of the GPRC6A in mice and subdiaphragmatic vagal deafferentation 
      in rats did not influence these anorectic effects. L-Arg stimulated GLP-1 and PYY 
      release in vitro and in vivo. Pharmacological blockade of GLP-1 and PYY receptors 
      did not influence the anorectic effect of L-Arg. L-Arg-mediated PYY release 
      modulated net ion transport across the gut mucosa. Intracerebroventricular 
      (i.c.v.) and intraperitoneal (i.p.) administration of L-Arg suppressed food 
      intake in rats. CONCLUSIONS: L-Arg reduced food intake and stimulated gut hormone 
      release in rodents. The anorectic effect of L-Arg is unlikely to be mediated by 
      GLP-1 and PYY, does not require GPRC6A signalling and is not mediated via the 
      vagus. I.c.v. and i.p. administration of L-Arg suppressed food intake in rats, 
      suggesting that L-Arg may act on the brain to influence food intake. Further work 
      is required to determine the mechanisms by which L-Arg suppresses food intake and 
      its utility in the treatment of obesity.
CI  - (c) 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Alamshah, A
AU  - Alamshah A
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - McGavigan, A K
AU  - McGavigan AK
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Spreckley, E
AU  - Spreckley E
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Kinsey-Jones, J S
AU  - Kinsey-Jones JS
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Amin, A
AU  - Amin A
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Tough, I R
AU  - Tough IR
AD  - Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and 
      Neuroscience, King's College London, London, UK.
FAU - O'Hara, H C
AU  - O'Hara HC
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Moolla, A
AU  - Moolla A
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Banks, K
AU  - Banks K
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - France, R
AU  - France R
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Hyberg, G
AU  - Hyberg G
AD  - AstraZeneca R&D, Molndal, Sweden.
FAU - Norton, M
AU  - Norton M
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Cheong, W
AU  - Cheong W
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Lehmann, A
AU  - Lehmann A
AD  - AstraZeneca R&D, Molndal, Sweden.
AD  - Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the 
      University of Gothenburg, Gothenburg, Sweden.
FAU - Bloom, S R
AU  - Bloom SR
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
FAU - Cox, H M
AU  - Cox HM
AD  - Wolfson Centre for Age-Related Diseases, Institute of Psychiatry, Psychology and 
      Neuroscience, King's College London, London, UK.
FAU - Murphy, K G
AU  - Murphy KG
AD  - Section of Endocrinology and Investigative Medicine, Department of Medicine, 
      Imperial College London, London, UK.
LA  - eng
GR  - BB/E52708X/1/BB_/Biotechnology and Biological Sciences Research Council/United 
      Kingdom
GR  - NC/K500379/1/NC3RS_/National Centre for the Replacement, Refinement and Reduction 
      of Animals in Research/United Kingdom
GR  - G0802390/MRC_/Medical Research Council/United Kingdom
GR  - MR/J010944/1/MRC_/Medical Research Council/United Kingdom
GR  - G7811974/MRC_/Medical Research Council/United Kingdom
GR  - G0000566/MRC_/Medical Research Council/United Kingdom
GR  - BB/I001816/1/BB_/Biotechnology and Biological Sciences Research Council/United 
      Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160401
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Appetite Depressants)
RN  - 0 (GPRC6A protein, mouse)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 106388-42-5 (Peptide YY)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 94ZLA3W45F (Arginine)
SB  - IM
MH  - Animals
MH  - Appetite Depressants/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Arginine/administration & dosage/adverse effects/*therapeutic use
MH  - Cells, Cultured
MH  - *Dietary Supplements/adverse effects
MH  - Energy Intake/drug effects
MH  - Energy Metabolism/drug effects
MH  - Gastrointestinal Agents/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Glucagon-Like Peptide 1/*agonists/blood/metabolism
MH  - In Vitro Techniques
MH  - Injections, Intraperitoneal
MH  - Injections, Intraventricular
MH  - Intestinal Mucosa/cytology/drug effects/metabolism/pathology
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Obesity/*diet therapy/drug therapy/metabolism/pathology
MH  - Peptide YY/*agonists/blood/metabolism
MH  - Random Allocation
MH  - Rats, Wistar
MH  - Receptors, G-Protein-Coupled/agonists/antagonists & 
      inhibitors/genetics/metabolism
MH  - Weight Loss/drug effects
PMC - PMC4982043
OTO - NOTNLM
OT  - GLP-1
OT  - animal pharmacology
OT  - body composition
OT  - energy regulation
OT  - obesity therapy
EDAT- 2016/02/13 06:00
MHDA- 2017/01/07 06:00
PMCR- 2016/08/12
CRDT- 2016/02/12 06:00
PHST- 2015/11/13 00:00 [received]
PHST- 2016/01/31 00:00 [revised]
PHST- 2016/02/07 00:00 [accepted]
PHST- 2016/02/12 06:00 [entrez]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2017/01/07 06:00 [medline]
PHST- 2016/08/12 00:00 [pmc-release]
AID - DOM12644 [pii]
AID - 10.1111/dom.12644 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2016 May;18(5):508-18. doi: 10.1111/dom.12644. Epub 2016 Apr 
      1.